Morphic Therapeutic, Inc. (a Wholly Owned Subsidiary Of Eli Lilly And Company)
Clinical trials sponsored by Morphic Therapeutic, Inc. (a Wholly Owned Subsidiary Of Eli Lilly And Company), explained in plain language.
-
New pill shows promise for ulcerative colitis sufferers
Disease control CompletedThis study tested an experimental drug called MORF-057 in 39 adults with moderate-to-severe ulcerative colitis, a chronic inflammatory bowel disease. The goal was to see if the drug could reduce gut inflammation and improve symptoms over 12 weeks. Participants took the drug by mo…
Phase: PHASE2 • Sponsor: Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) • Aim: Disease control
Last updated May 26, 2026 04:22 UTC
-
New drug MORF-440 tested in healthy people for first time
Knowledge-focused CompletedThis early-stage study tested the safety of a new drug called MORF-440 in 80 healthy adults. Participants received either a single dose or multiple doses to see if it causes side effects. The study is complete and does not aim to treat any disease.
Phase: PHASE1 • Sponsor: Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) • Aim: Knowledge-focused
Last updated May 18, 2026 12:14 UTC